UK markets open in 3 hours 3 minutes

Molecular Partners AG (0QXX.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
3.9900-0.0600 (-1.48%)
At close: 06:01PM GMT

Molecular Partners AG

Wagistrasse 14
Schlieren 8952
41 44 755 77 00

Full-time employees175

Key executives

NameTitlePayExercisedYear born
Dr. Patrick Amstutz Ph.D.Co-Founder, CEO, Member of Management Board & Director620kN/A1975
Dr. Michael Tobias Stumpp Ph.D.Co-Founder, Executive VP of Projects & Member of Management BoardN/AN/A1972
Mr. Robert HendriksVice President of FinanceN/AN/AN/A
Mr. Alexander ZurcherCOO & Member of Management BoardN/AN/A1975
Ms. Renate GloggnerExecutive VP of People & Community and Member of Management BoardN/AN/A1970
Mr. Daniel Steiner Ph.D.Senior Vice President of ResearchN/AN/AN/A
Mr. Seth D. LewisSenior Vice President of Investor Relations, Communications & StrategyN/AN/AN/A
Mr. Michael PitznerGeneral Counsel, Compliance Officer, Senior VP Legal & Business DevelopmentN/AN/AN/A
Dr. Pamela A. Trail Ph.D.Strategic ConsultantN/AN/A1956
Ms. Anne Goubier D.V.M., Ph.D.Senior Vice President of BiologyN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CHF.


Molecular Partners AG operates as a clinical-stage biopharmaceutical company, develops ankyrin proteins for the treatment of oncology and virology diseases. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular age-related macular degeneration, as well as for diabetic macular edema; and ensovibep (MP0420), a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, a DARPin molecule, which activates T-cells and other immune cells; MP0317, that allows tumor-restricted immune-cell CD40 activation for the treatment of fibroblast activation protein (FAP) positive cancers, which is in Phase I clinical trials; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274, that uses HER2-specific DARPin binding proteins. It also develops MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor (VEGF)and hepatocyte growth factor. Molecular Partners AG has license and research collaboration agreements with Novartis AG to develop DARPin-conjugated radioligand therapies; as well as other third-party collaborators. It also has a collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Corporate governance

Molecular Partners AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.